Tenaya Therapeutics, Inc. (TNYA): Price and Financial Metrics
TNYA Price/Volume Stats
Current price | $5.26 | 52-week high | $8.09 |
Prev. close | $5.16 | 52-week low | $1.66 |
Day low | $5.06 | Volume | 70,577 |
Day high | $5.30 | Avg. volume | 624,234 |
50-day MA | $5.16 | Dividend yield | N/A |
200-day MA | $3.86 | Market Cap | 412.99M |
TNYA Stock Price Chart Interactive Chart >
Tenaya Therapeutics, Inc. (TNYA) Company Bio
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest TNYA News From Around the Web
Below are the latest news stories about TENAYA THERAPEUTICS INC that investors may wish to consider to help them evaluate TNYA as an investment opportunity.
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 35th Annual Piper Sandler Healthcare Conference taking place in New York, NY. Details of participation are as follows: Fireside ChatDate: Novem |
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateCommenced Patient Dosing in MyPeak-1TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at HFSA 2023 TN-401 for PKP2-Associated ARVC Received FDA Clearance to Begin First-in-Human Clinical Testing and Fast Track Designation SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechn |
Institutional investors have a lot riding on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) with 38% ownershipKey Insights Significantly high institutional ownership implies Tenaya Therapeutics' stock price is sensitive to their... |
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyPKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated Robust Reduction of Ventricular Arrhythmias and Extended Survival in Knockout Models of Disease After a Single Dose SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and |
We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
TNYA Price Returns
1-mo | -9.93% |
3-mo | 62.35% |
6-mo | 106.27% |
1-year | 94.81% |
3-year | N/A |
5-year | N/A |
YTD | 62.35% |
2023 | 61.19% |
2022 | -89.39% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...